3 August 2023PharmaMarisa Woutersen

BMS and AstraZeneca settle dispute for $510m

Joint stipulations approved by federal judge to dismiss three lawsuits alleging patent infringement on cancer immunotherapies | Companies settle early ‘to save time and attention’ say reports.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Italy’s Biofer falls short in Fed Circ appeal over key claim wording

7 September 2026 A single phrase in a patent has proved decisive in Biofer’s infringement fight with Vifor, with the Federal Circuit exposing the risks of small claim-drafting choices for life sciences companies.

Pharma

Teva faces scrutiny over efforts to curb generic competition

27 August 2026 Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers.

Pharma

Teva and Aurinia settle generics dispute over lupus drug, voclosporin

21 August 2026 Under the terms of the agreement, which resolves all patent litigation between the biopharma rivals, Teva now has a launch date for its own version of Aurinia's Lupkynis.

More features

Abbott clinches 18-country PI in glucose monitoring feud

UK firm hires head of IP with commercial and technical nous

Italy’s Biofer falls short in Fed Circ appeal over key claim wording

G 1/25: EPO settles controversial patent description question

California votes for law to restrict use of genAI by lawyers

Sun Pharma import ban back in force after Squires intervention

10x Genomics wins latest round in Parse patent dispute

White & Case life sciences co-leader moves firms

BMS and AstraZeneca settle dispute for $510m

More on this story

Editor's picks

Editor's picks

More features